GlaxoSmithKline Financial Statements From 2010 to 2020

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC financial statements provide useful quartarly and yearly information to potential investors in GlaxoSmithKline PLC about the current and past financial position of the company, as well as its overall management performance and changes in basic fundamentals over time. There are currently one hundred fourteen fundamental trends for GlaxoSmithKline PLC that can be evaluated and compared over time across competitors. Please compare all of GlaxoSmithKline PLC regular fundamentals against the fundamentals between 2010 and 2020 to make sure the company is sustainable this year. GlaxoSmithKline PLC Interest Coverage is increasing as compared to previous years. The last year's value of Interest Coverage was reported at 146.89. The current Long Term Debt to Equity is estimated to increase to 2.70, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are estimated to decrease to under 6 B.

Search Fundamental Trends

 
Refresh
Check GlaxoSmithKline PLC financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Direct Expenses of 10 B, Consolidated Income of 4.6 B or Cost of Revenue of 11.4 B, as well as many exotic indicators such as Interest Coverage of 158, Long Term Debt to Equity of 2.7 or Calculated Tax Rate of 23.02. This can be a perfect complement to check GlaxoSmithKline PLC Valuation or Volatility. It can also complement various GlaxoSmithKline PLC Technical models. Please check the analysis of GlaxoSmithKline PLC Correlation with competitors.

  GlaxoSmithKline PLC Revenues

GlaxoSmithKline PLC Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets71.3 B79.7 B53.3 B
Increasing
Slightly volatile
Cash and Equivalents4.6 B4.7 B4.9 B
Decreasing
Slightly volatile
Investments2.1 B2.2 B1.6 B
Increasing
Slightly volatile
Investments Current89.7 M79 M105.7 M
Decreasing
Slightly volatile
Investments Non CurrentB2.2 B1.5 B
Increasing
Slightly volatile
Property Plant and Equipment Net11.6 B11.3 B10 B
Increasing
Slightly volatile
Inventory5.8 B5.9 B4.8 B
Increasing
Slightly volatile
Tax Assets4.2 B4.4 B3.4 B
Increasing
Slightly volatile
Trade and Non Trade Receivables7.2 B7.2 BB
Increasing
Slightly volatile
Trade and Non Trade Payables14 B14.9 B11.2 B
Increasing
Slightly volatile
Goodwill and Intangible Assets32.9 B41.5 B20.9 B
Increasing
Slightly volatile
Total Liabilities57 B61.3 B44.9 B
Increasing
Slightly volatile
Shareholders Equity12.3 B11.4 B6.3 B
Increasing
Very volatile
Accumulated Retained Earnings Deficit4.9 B4.5 B237.1 M
Decreasing
Stable
Current Assets19.7 B19.5 B16.6 B
Increasing
Slightly volatile
Assets Non Current51.6 B60.2 B36.7 B
Increasing
Slightly volatile
Current Liabilities22.5 B24.1 B17.8 B
Increasing
Slightly volatile
Liabilities Non Current34.5 B37.3 B27 B
Increasing
Slightly volatile
Tax Liabilities3.9 B4.6 B2.8 B
Increasing
Slightly volatile
Total Debt27.1 B30.5 B20.2 B
Increasing
Slightly volatile
Debt Current5.5 B6.9 B3.6 B
Increasing
Slightly volatile
Debt Non Current21.7 B23.6 B16.6 B
Increasing
Slightly volatile
Shareholders Equity USD16.2 B15 B9.2 B
Decreasing
Stable
Cash and Equivalents USD6.4 B6.2 B7.2 B
Decreasing
Slightly volatile
Total Debt USD37.2 B40.1 B29.1 B
Increasing
Slightly volatile
Accounts Payable3.5 B4.1 B3.1 B
Increasing
Slightly volatile
ReceivablesB6.9 B5.6 B
Increasing
Slightly volatile
Inventories5.1 B5.9 B4.7 B
Increasing
Slightly volatile

GlaxoSmithKline PLC Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues33.9 B33.8 B28.4 B
Increasing
Slightly volatile
Cost of Revenue11.4 B11.9 B9.2 B
Increasing
Slightly volatile
Selling General and Administrative Expense11.6 B11.4 B9.5 B
Increasing
Slightly volatile
Research and Development Expense4.7 B4.6 BB
Increasing
Slightly volatile
Operating Expenses15.3 B14.9 B12.8 B
Increasing
Slightly volatile
Interest Expense935.4 M912 M796 M
Increasing
Slightly volatile
Income Tax Expense1.1 B953 M1.3 B
Decreasing
Slightly volatile
Consolidated Income4.6 B5.3 B4.5 B
Decreasing
Stable
Net Income to Non Controlling Interests672.2 M623 M294.2 M
Increasing
Slightly volatile
Net Income4.1 B4.6 B4.2 B
Decreasing
Stable
Net Income Common Stock4.1 B4.6 B4.2 B
Decreasing
Stable
Weighted Average Shares5.9 B5.4 B5.4 B
Increasing
Slightly volatile
Weighted Average Shares Diluted5.5 BBB
Increasing
Stable
Earning Before Interest and Taxes EBITB6.5 B6.4 B
Decreasing
Slightly volatile
Revenues USD40.6 B44.4 B40.5 B
Decreasing
Stable
Net Income Common Stock USD5.8 B6.1 B6.3 B
Decreasing
Slightly volatile
Earning Before Interest and Taxes USD8.4 B8.6 B9.5 B
Decreasing
Slightly volatile
Gross Profit22.5 B21.9 B19.2 B
Increasing
Slightly volatile
Operating Income6.2 BB6.3 B
Decreasing
Slightly volatile
Direct Expenses10 B11.9 BB
Increasing
Slightly volatile

GlaxoSmithKline PLC Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(1.3 B)(1.2 B)(1.2 B)
Decreasing
Stable
Net Cash Flow Business Acquisitions and Disposals(3.7 B)(3.6 B)(151.6 M)
Decreasing
Stable
Net Cash Flow Investment Acquisitions and Disposals(192.9 M)(188 M)37.3 M
Decreasing
Stable
Net Cash Flow from Financing(2 B)(1.8 B)(4.9 B)
Increasing
Stable
Issuance Repayment of Debt Securities 3.8 B3.5 B1.6 B
Increasing
Slightly volatile
Issuance Purchase of Equity Shares55 M51 M(420.6 M)
Increasing
Slightly volatile
Payment of Dividends and Other Cash Distributions (4.3 B)(4 B)(3.9 B)
Decreasing
Slightly volatile
Net Cash Flow from Investing(5.5 B)(5.4 B)(1.5 B)
Decreasing
Stable
Net Cash Flow from Operations9.6 B9.5 BB
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (84.2 M)(82 M)(40.2 M)
Increasing
Stable
Net Cash Flow or Change in Cash and Cash Equivalents891.2 M826 M106.3 M
Increasing
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share1.671.8781.727
Decreasing
Stable
Earnings per Diluted Share1.651.8521.7051
Decreasing
Stable
Earnings per Basic Share USD2.342.4712.5781
Decreasing
Slightly volatile
Dividends per Basic Common Share2.392.0382.3134
Increasing
Very volatile
Return on Average Equity0.90.6121.0601
Increasing
Slightly volatile
Return on Average Assets0.07180.0670.0899
Decreasing
Slightly volatile
Return on Invested Capital0.190.1740.223
Decreasing
Slightly volatile
Gross Margin0.630.6490.6741
Decreasing
Slightly volatile
Profit Margin0.140.1380.1553
Decreasing
Slightly volatile
EBITDA Margin0.20.1930.2315
Decreasing
Slightly volatile
Return on Sales0.20.1930.2315
Decreasing
Slightly volatile
Asset Turnover0.50.490.5666
Decreasing
Slightly volatile
Payout Ratio0.840.8251.4411
Increasing
Stable
Enterprise Value over EBITDA19.7618.20817.5596
Increasing
Slightly volatile
Enterprise Value over EBIT21.0620.717.8871
Increasing
Slightly volatile
Price to Earnings Ratio25.2919.01625.1244
Increasing
Stable
Sales per Share15.216.51315.2923
Decreasing
Slightly volatile
Price to Sales Ratio3.12.8462.8334
Increasing
Stable
Price to Book Value9.098.422(77.3813)
Decreasing
Stable
Debt to Equity Ratio5.85.378(60.8092)
Decreasing
Stable
Dividend Yield0.05410.0430.0546
Increasing
Stable
Current Ratio0.860.810.9882
Decreasing
Slightly volatile
Free Cash Flow per Share3.123.1092.5641
Increasing
Stable
Book Value per Share4.574.2412.3602
Decreasing
Very volatile
Tangible Assets Book Value per Share14.3814.19412.1813
Increasing
Slightly volatile
Total Assets Per Share12.7715.971610.5974
Increasing
Slightly volatile
Cash Flow Per Share1.371.60731.2647
Increasing
Slightly volatile
Return on Investment23.218.275623.4267
Decreasing
Stable
Operating Margin22.2519.582920.7872
Decreasing
Stable
Calculated Tax Rate23.0215.503525.4233
Decreasing
Stable
Receivables Turnover4.855.21224.9869
Increasing
Slightly volatile
Inventory Turnover1.922.0771.9532
Decreasing
Very volatile
PPandE Turnover3.333.15372.9176
Increasing
Very volatile
Cash and Equivalents Turnover6.557.86715.8022
Increasing
Slightly volatile
Accounts Payable Turnover10.138.66719.6625
Decreasing
Slightly volatile
Accrued Expenses Turnover4.993.82575.1283
Decreasing
Slightly volatile
Interest Coverage15814746.4006
Increasing
Slightly volatile
Long Term Debt to Equity2.72.06843.7947
Increasing
Stable
Quick Ratio0.630.48480.6513
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets(5.8713)(5.7208)(1.8862)
Decreasing
Slightly volatile
Revenue to Assets0.550.42360.5573
Decreasing
Slightly volatile

GlaxoSmithKline PLC Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share1.671.8781.727
Decreasing
Stable
Earnings per Diluted Share1.651.8521.7051
Decreasing
Stable
Earnings before Tax5.2 B5.6 B5.6 B
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDAB6.5 B6.4 B
Decreasing
Slightly volatile
Earnings per Basic Share USD2.342.4712.5781
Decreasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD8.4 B8.6 B9.5 B
Decreasing
Slightly volatile
Dividends per Basic Common Share2.392.0382.3134
Increasing
Very volatile
Market Capitalization113.7 B126.4 B113.2 B
Decreasing
Stable
Enterprise Value157.7 B156 B134.4 B
Increasing
Stable
Invested Capital37.7 B39.9 B29.8 B
Increasing
Slightly volatile
Average Equity6.4 B7.6 B5.5 B
Decreasing
Slightly volatile
Average Assets64.5 B68.9 B50.8 B
Increasing
Slightly volatile
Invested Capital Average36.1 B37.4 B29.2 B
Increasing
Slightly volatile
Tangible Asset Value38.4 B38.2 B32.3 B
Increasing
Slightly volatile
Return on Average Equity0.90.6121.0601
Increasing
Slightly volatile
Return on Average Assets0.07180.0670.0899
Decreasing
Slightly volatile
Free Cash Flow8.3 B8.4 B6.8 B
Increasing
Stable
Return on Invested Capital0.190.1740.223
Decreasing
Slightly volatile
Gross Margin0.630.6490.6741
Decreasing
Slightly volatile
Profit Margin0.140.1380.1553
Decreasing
Slightly volatile
EBITDA Margin0.20.1930.2315
Decreasing
Slightly volatile
Return on Sales0.20.1930.2315
Decreasing
Slightly volatile
Asset Turnover0.50.490.5666
Decreasing
Slightly volatile
Payout Ratio0.840.8251.4411
Increasing
Stable
Enterprise Value over EBITDA19.7618.20817.5596
Increasing
Slightly volatile
Enterprise Value over EBIT21.0620.717.8871
Increasing
Slightly volatile
Price to Earnings Ratio25.2919.01625.1244
Increasing
Stable
Sales per Share15.216.51315.2923
Decreasing
Slightly volatile
Price to Sales Ratio3.12.8462.8334
Increasing
Stable
Price to Book Value9.098.422(77.3813)
Decreasing
Stable
Debt to Equity Ratio5.85.378(60.8092)
Decreasing
Stable
Dividend Yield0.05410.0430.0546
Increasing
Stable
Current Ratio0.860.810.9882
Decreasing
Slightly volatile
Working Capital(4.7 B)(4.6 B)(1.4 B)
Decreasing
Slightly volatile
Free Cash Flow per Share3.123.1092.5641
Increasing
Stable
Book Value per Share4.574.2412.3602
Decreasing
Very volatile
Tangible Assets Book Value per Share14.3814.19412.1813
Increasing
Slightly volatile
Total Assets Per Share12.7715.971610.5974
Increasing
Slightly volatile
Cash Flow Per Share1.371.60731.2647
Increasing
Slightly volatile
Revenue Per Employee297.5 K339.5 K283.6 K
Increasing
Slightly volatile
Net Income Per Employee47.3 K46.7 K39.9 K
Increasing
Very volatile
Return on Investment23.218.275623.4267
Decreasing
Stable
Operating Margin22.2519.582920.7872
Decreasing
Stable
Calculated Tax Rate23.0215.503525.4233
Decreasing
Stable
Receivables Turnover4.855.21224.9869
Increasing
Slightly volatile
Inventory Turnover1.922.0771.9532
Decreasing
Very volatile
PPandE Turnover3.333.15372.9176
Increasing
Very volatile
Cash and Equivalents Turnover6.557.86715.8022
Increasing
Slightly volatile
Accounts Payable Turnover10.138.66719.6625
Decreasing
Slightly volatile
Accrued Expenses Turnover4.993.82575.1283
Decreasing
Slightly volatile
Interest Coverage15814746.4006
Increasing
Slightly volatile
Long Term Debt to Equity2.72.06843.7947
Increasing
Stable
Quick Ratio0.630.48480.6513
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets(5.8713)(5.7208)(1.8862)
Decreasing
Slightly volatile
Revenue to Assets0.550.42360.5573
Decreasing
Slightly volatile

GlaxoSmithKline Fundamental Market Drivers

Forward Price Earnings13.61
Average Daily Volume Last 10 Day2.54M
Shares Short Prior Month11.2M
Average Daily Volume In Three Month3.6M
Date Short Interest15th of June 2020
Fifty Day Average41.43
Two Hundred Day Average42.43

GlaxoSmithKline Upcoming Events

Upcoming Quarterly Report22nd of July 2020
Next Earnings Report4th of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Anouncement30th of June 2019

About GlaxoSmithKline PLC Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. GlaxoSmithKline PLC investors use historical funamental indicators, such as GlaxoSmithKline PLC's revenue or net income, to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on GlaxoSmithKline PLC Financial Statements. Understanding these patterns can help to make the right decision on long term investment in GlaxoSmithKline PLC. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check the analysis of GlaxoSmithKline PLC Correlation with competitors. Please also try Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page